Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week

Two oral presentations to highlight new 76-week data showing sustained proteinuria reduction and continued eGFR stabilization with a consistent long-term safety profileAdditional presentations to highlight nephrologist perspectives on gaps in current care practices and limited treatment options for antibody-mediated rejection (AMR)Presentations on the role of felzartamab, an investigational anti-CD38 monoclonal antibody, in multiple immune-mediated kidney diseases will also be featured CAMBRIDGE